Misbranded Peptides From China: What a Federal Physician Indictment Means for Florida Med Spas and Clinics

A federal grand jury in Salt Lake City returned an indictment on April 1, 2026 against a licensed osteopathic physician who allegedly bought peptides from a supplier in China, made his own labels for the vials, and sold the products to more than 200 patients at his clinic. The order list included tirzepatide, semaglutide, retatrutide, BPC-157, TB500, ipamorelin, CJC 1295, GHK-Cu, and NAD+. If you operate a med spa, a wellness clinic, or a weight loss practice anywhere near those compounds, the fact pattern in this case probably looks like a normal week in your industry. Federal prosecutors chose this case because the conduct is common, and they intend it to be read by everyone else doing the same thing.

The Utah indictment describes a physician who ordered peptides from China, applied his own labels, and sold the products to more than 200 patients. That fact pattern is common in the wellness and med spa industry. Federal prosecutors know it.

A Physician, a Middleman, and Unlabeled Vials From China

According to the U.S. Attorney's Office for the District of Utah, the 39-year-old physician used an intermediary to order discounted peptides from a Chinese supplier between February 2024 and April 2025. The products allegedly arrived in unlabeled vials and pill bottles. The physician then made and affixed his own labels before clinic staff sold the products to patients. None of the labels disclosed the name and place of business of the manufacturer, packer, or distributor, which 21 U.S.C. 352(b) requires for any drug in interstate commerce.

The government alleges he knew the peptides were not FDA approved and were not supported by reliable testing or clinical trials, and that he bought them precisely because they were cheap. The indictment charges receipt in interstate commerce and delivery for pay of misbranded drugs with intent to defraud or mislead, along with aiding and abetting under 18 U.S.C. 2.

One allegation deserves special attention: prosecutors claim that, at one point, the physician asked his intermediary to form a new LLC that would keep buying peptides from the Chinese supplier and sell them directly to his patients. The government will present that workaround as its best evidence of intent.

An indictment is an allegation, and the defendant is presumed innocent. But the structure of the case shows how these prosecutions are built.

The government's evidence rests on the vials themselves: no manufacturer name, no place of business, no FDA approval. When the physician applied his own labels, he became the distributor of record for a misbranded drug in interstate commerce.

Peptide Enforcement Is Now a Criminal Program, Not a Paperwork Problem

For years, gray-market peptides drew warning letters and not much else. That period is over. The Utah case was investigated jointly by the FDA Office of Criminal Investigations and the state professional licensing division, the same pairing now appearing in peptide and GLP-1 matters across the country. FDA has published its position on unapproved GLP-1 drugs and has sent warning letters to research peptide sellers stating that "research chemicals only" disclaimers do not change a product's status as a drug when the seller markets it for human use. A September 2025 letter to an online seller of compounded retatrutide, semaglutide, and tirzepatide cited the same receipt-and-delivery provision now carrying felony counts in Utah.

Florida is squarely in the crosshairs. FDA-OCI has been active in this state for several years and filed 2026 federal charges in the Middle District of Florida over research-use-only semaglutide sales. The SDFL has a long track record on healthcare fraud. This enforcement pattern is not a warning. It is an active program.

FDA-OCI and state professional licensing boards are now coordinating on peptide cases nationwide. The same joint investigation model used in Utah is operating in Florida. These are not regulatory audits. They are criminal investigations.

What the Charges Mean for Florida Providers

The misbranding charges in the Utah indictment are not complicated. If a drug moves in interstate commerce, it must carry complete labeling. If a provider sells it to patients, the provider is on the hook for that label. Intent to defraud or mislead is what converts a misdemeanor into a felony, and the government builds that element from emails, orders, bank records, and conversations between the provider and the supplier.

In Florida, the same fact pattern is available to prosecutors: a clinic ordering from a Chinese supplier, applying its own labels, selling to patients, and telling patients the products are safe while simultaneously knowing they are not FDA-approved. That is enough to open a federal criminal investigation.

The best defense position is the one you occupy before the investigation becomes an indictment. At the pre-indictment stage, prosecutors are still weighing the strength of their evidence, the cooperation value of the target, and the return on resources. A provider who already has counsel, who has preserved records correctly, and who understands the government's theory of the case is in a fundamentally different position than one who has done nothing.

"The best defense window is before indictment, while prosecutors are still deciding between declination, misdemeanor counts, and felony charges."— Aaron M. Cohen, Principal Attorney

What You Should Do Now

If your clinic, pharmacy, or wellness practice has ordered peptides from a Chinese supplier, applied its own labels, or sold unapproved compounds to patients, you are in the same fact pattern as the Utah indictment. The time to consult a federal criminal defense attorney is now, not after you receive a target letter or a search warrant.

AMC Defense Law represents physicians, clinics, med spas, and wellness businesses in federal healthcare fraud and FDA enforcement matters across Florida and nationwide. Aaron M. Cohen is available 24 hours a day.

AMC Defense Law defends physicians, clinics, med spas, and wellness businesses facing federal healthcare fraud and FDA enforcement investigations across Florida and nationwide.

If you operate a med spa, wellness clinic, or practice in this space and have questions about your federal criminal exposure, call Aaron M. Cohen, 24 hours a day to get help.